A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil



Status:Completed
Conditions:Alzheimer Disease
Therapuetic Areas:Neurology
Healthy:No
Age Range:50 - Any
Updated:2/1/2019
Start Date:June 16, 2011
End Date:November 4, 2011

Use our guide to learn which trials are right for you!

A Phase 1b, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Sequential Dose Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease on Donepezil

This study is intended to determine the safety and tolerability of ASP0777 in subjects with
Alzheimer's Disease (AD) taking a stable dose of donepezil.


Inclusion Criteria:

- Subject has a Mini-Mental Status Exam score of 18-26

- Subject has a diagnosis of "probable" Alzheimer's Disease

- Subject has used donepezil for at least 3 months and has been on a stable dose for at
least 6 weeks prior to screening

- Subject has a reliable adult who is residing with him/her during the outpatient
portion of the study

- Subject is medically stable

- Subject has adequate cognitive, hearing, vision, and language skills

- Subject is able to ingest oral tablets

Exclusion Criteria:

- Subject has received any investigational product in another clinical study or
post-marketing clinical study within past 3 months

- Subject has any clinically significant abnormal laboratory tests

- Subject is a female who is pregnant, lactating or of childbearing potential who
refuses to use a form of contraception during the study

- Subject has a history of a drug allergy or intolerance to memantine or a related
compound

- Subject is currently using anti-dementia drugs (except for donepezil) or has used any
such drugs within the last 4 weeks

- Subject has a score of 2 on item 16 of Cornell Scale for Depression in Dementia (CSDD)
or has an overall CSDD score > 10

- Subject is using off-label medicines, non-medicinal compounds, or dietary aids/food
supplements to improve cognition that have not been at a stable dose for at least 4
weeks prior to Screening and/or are anticipated to change dosing regimen during the
study

- Subject has a history of drug or alcohol abuse within the past 12 months or subject
consumes > 1 drink of alcohol daily, or is unable to refrain from alcohol during the
study

- Subject is a current smoker or recently quit smoking (within the past 12 months)

- Subject has a clinically significant medical condition that is unstable or is likely
to become unstable during the course of the study

- Subject has history of seizures, other than febrile seizures during infancy

- Subject has history of repeated falls within past 6 months

- Subject has a major psychiatric illness or has received treatment for symptoms of a
major psychiatric illness within past 1 year. Mild psychiatric disorders are allowable
We found this trial at
2
sites
San Diego, California 92103
?
mi
from
San Diego, CA
Click here to add this to my saved trials
911 E. Hallandale Beach Blvd
Hallandale Beach, Florida 33009
954-455-5757
?
mi
from
Hallandale Beach, FL
Click here to add this to my saved trials